Implantable medical device with nerve and cardiac electrodes
The implantable medical device with a dual-electrode lead body for nerve stimulation and cardiac sensing addresses the challenge of unintended cardiac tissue activation during neuromodulation, ensuring precise therapy delivery and reducing procedure time.
Patent Information
- Application Number
- PCT/IB2026/054125
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-13
- Filing Date
- 2026-04-27
- Publication Date
- 2026-11-19
AI Technical Summary
Existing implantable medical devices face challenges in delivering electrical neuromodulation therapy to nerve tissue while avoiding unintentional stimulation of surrounding cardiac tissue, leading to arrhythmias such as AF.
An implantable medical device with a single lead body featuring a first electrode for nerve tissue stimulation and a second electrode for cardiac tissue sensing, positioned to ensure precise nerve stimulation without affecting cardiac tissue, thereby reducing the risk of arrhythmias.
The device allows for precise nerve tissue stimulation and accurate management of cardiac arrhythmia by minimizing unintended cardiac tissue activation, simplifying the implantation procedure, and reducing the time required for lead placement.
Smart Images

Figure IB2026054125_19112026_PF_FP_ABST
Abstract
Description
Atty Ref. No. A0013308W001IMPLANTABLE MEDICAL DEVICE WITH NERVE AND CARDIAC ELECTRODES
[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 804,918, filed May 13, 2025, the entire content of which is incorporated herein by reference.TECHNICAL FIELD
[0002] This disclosure relates generally to implantable medical devices and methods configured to provide electrical stimulation for therapy, and more particularly, for treating heart arrhythmias.BACKGROUND
[0003] Medical device systems have been devised to provide electrical neuromodulation therapy to modify the functioning of the heart. For example, delivery of electrical therapy to the vagus nerve may therapeutically modulate, e.g., slow, the conduction response of the atrioventricular (AV) node, e.g., to atrial fibrillation (AF).SUMMARY
[0004] Implantable medical devices, such as pacemakers, may be configured to provide electrical neuromodulation therapy to nerve tissue of the heart using electrodes to treat heart arrhythmias, e.g., to slow conduction of AF. However, the electrical signal delivered during the neuromodulation therapy may unintentionally stimulate cardiac tissue. This results in unintentional cardiac tissue activation and may cause a patient to have arrhythmia, such as AF.
[0005] Examples disclosed herein address these challenges by providing one lead body that is configured to deliver neuromodulation therapy to a nerve tissue and to sense activity of surrounding cardiac tissue. Accordingly, a clinician may be able to deliver a neuromodulation therapy to a nerve tissue and sense cardiac tissue response with a single lead body using the techniques disclosed herein. In some examples, the clinician may also be able to pace cardiac tissue with the same lead body using the techniques disclosed herein. In comparison to having two separate lead bodies, having these functions on one lead body reduces the time needed for lead implantation and may simplify the procedure.Atty Ref. No. A0013308W001Additionally, the one lead body may be configured such that the delivered neuromodulation therapy may advantageously stimulate only nerve tissue, decreasing the chances of unintentionally stimulating the surrounding cardiac tissues. Thus, examples disclosed herein may advantageously improve arrythmia treatment.
[0006] In some examples, the implantable medical device comprises an elongated body, a first electrode, a second electrode, and circuitry. The elongated body includes a proximal portion and a distal portion. The first electrode extends distally from the distal portion and is configured to position proximate to a nerve tissue of a heart of a patient when the elongated body is implanted within the heart. The second electrode is supported by the distal portion. The circuitry is connected to the first electrode and the second electrode via the proximal portion of the elongated body. The circuitry is configured to cause the first electrode to deliver a stimulating signal to the nerve tissue of the heart. The circuitry is also configured to cause the second electrode to sense an electrical signal from a cardiac tissue of the heart. In some examples, the circuitry is configured to pace cardiac tissue of the heart.
[0007] In some examples, a method includes delivering a first stimulating electrical signal to a nerve tissue of a heart of a patient and sensing an electrical signal of a cardiac tissue of the heart. The step of delivering and sensing is done by an implantable medical device with an elongated body having a proximal portion and a distal portion. A first electrode extends distally from the distal portion of the elongated body and a second electrode is supported by the distal portion. The stimulating electrical signal is delivered via the first electrode. The sensing is done via the second electrode. In some examples, the method includes pacing the cardiac tissue of the heart via the second electrode.
[0008] The details of one or more examples are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.BRIEF DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1 A is a conceptual diagram of an example implantable medical device implanted in a patient’s heart in accordance with techniques of this disclosure.
[0010] FIG. IB is a conceptual diagram of an example medical device system in accordance with techniques of this disclosure.Atty Ref. No. A0013308W001
[0011] FIG. 1C is a conceptual diagram of an example implantable medical device in accordance with techniques of this disclosure.
[0012] FIG. 2A is an enlarged conceptual diagram of the medical device of FIG. 1C, in accordance with techniques of this disclosure.
[0013] FIG. 2B is a conceptual diagram of the implantable medical device of FIG. 2A assembled in accordance with techniques of this disclosure.
[0014] FIG. 2C is a conceptual view of a distal portion of the implantable medical device of FIG. 2A in accordance with the techniques of this disclosure.
[0015] FIG. 3 is a conceptual illustration of an implantation site for an implantable medical device in accordance with the techniques of this disclosure.
[0016] FIG. 4 is a close-up illustration of an implantable medical device implanted in an implantation site in accordance with the techniques of this disclosure.
[0017] FIG. 5 is a flow diagram illustrating an example technique for providing neuromodulation therapy and cardiac sensing to a heart of a patient in accordance with the techniques of this disclosure.
[0018] FIG. 6 is a flow diagram illustrating an example technique for providing neuromodulation therapy and cardiac sensing and pacing to a heart of a patient in accordance with the techniques of this disclosure.
[0019] FIG. 7 is a functional block diagram of an example circuitry of an implantable medical device in accordance with the techniques of this disclosure.DETAILED DESCRIPTION
[0020] Many therapeutic techniques include delivery of therapeutic electrical signals to certain tissue (e.g., nerve tissue) within the human body to treat certain diseases. For example, a lead with one or more electrodes may be implanted within a heart of a patient. A medical device (e.g., a pacemaker) attached to the lead may include circuitry that provides electrical neuromodulation therapy to a vagus nerve of the patient. Specifically, the therapy may target the ganglia plexus near the AV node via the one or more electrodes to control the AV nodal conduction. The vagus nerve may innervate the AV node (AVN), and AVN stimulation may thereby control a ventricular rate of the heart. In particular, electrical neuromodulation of the vagus nerve may significantly reduce the ventricular rateAtty Ref. No. A0013308W001of the patient’s heart during atrial fibrillation (AF). This may help manage cardiac arrhythmia and regulate the patient’s heart.
[0021] However, it may be difficult to affect only the target tissue, and not also affect non-target tissue surrounding the target tissue. For example, in the heart, nerve tissue may surround or be in close proximity to non-nerve (e.g., cardiac) tissue. Accordingly, a lead intended to deliver therapy to nerve tissue may also unintentionally deliver electrical pulses to non-nerve tissue. This may be due to a variety of factors, including the location of the electrodes on the lead body, the electrical field generated by the leads / electrodes, the placement of the lead / electrodes relative to the target and non-target tissue, etc. In the heart, the unintentional stimulation may cause activation of the cardiac tissue, which may lead to atrial cardiac arrhythmia (e.g., AF, atrial tachycardia (AT), etc.)
[0022] Examples disclosed herein address these challenges by providing an implantable medical device with an elongated body (e.g., a lead body) having a first electrode for nerve tissue stimulation and a second electrode for cardiac tissue sensing. The first electrode is configured to be positioned next to a nerve tissue of the heart when the medical device is implanted within the heart. In this manner, the first electrode delivers stimulation energy to the target nerve tissue and the second electrode senses cardiac tissue that is not a target of nerve tissue stimulation. In some examples, the second electrode may additionally deliver cardiac pacing stimulation to the cardiac tissue. Accordingly, examples disclosed herein stimulate nerve tissue and sense and / or pace cardiac tissue with the same lead body. This may help to ensure that surrounding cardiac tissue are not being affected by the stimulation energy meant for nerve tissue. Device delivery, implantation procedure, and overall patient treatment may also be simplified with one lead that is configured to both stimulate nerve tissue and sense and / or pace cardiac tissue as this reduces the number of leads used to perform the tasks.
[0023] Additionally, in the implantable medical devices disclosed herein, the placement of first and second electrodes on the lead body (e.g., in relation to each other and surrounding tissue of the implantation site) and their respective electrical properties allow for the electrical signal delivered by the first electrode to stimulate the target nerve tissue and not the non-target cardiac tissue. In other words, stimulation of the nerve tissue does not unintentionally activate cardiac tissue. In some examples, both the first and second electrodes are positioned distally on the implantable medical device with the firstAtty Ref. No. A0013308W001electrode extending more distally than the second electrode. In some examples, the first electrode includes a portion that is electrically active and another portion that is electrically insulated. These features allow for the electrical stimulation field generated by the first electrode to be of appropriate size to affect target nerve tissue and not affect nontarget cardiac tissue. Accordingly, the examples disclosed herein may allow for more precise nerve tissue stimulation and more accurate management of cardiac arrhythmia.
[0024] Although described primarily herein with reference to a medical lead implanted in a heart of a patient and configured to deliver electrical neuromodulation therapy to a vagus nerve of the patient, the assemblies and techniques described herein may be applicable to systems including medical leads configured to deliver other therapies and / or configured to be implanted in different locations within a patient. These other locations may include locations in the ventricles and vessels opening into the heart where nerve tissue is in close proximity and / or surrounded by cardiac tissue, including but not limited to other locations in the atrium.
[0025] Referring now to the figures, FIG. 1 A is a conceptual diagram of an example implantable medical device 100 in accordance with techniques of this disclosure.Implantable medical device 100 includes an elongated body, e.g., an implantable medical lead, and a housing 190. Elongated body 110 includes a distal portion 113 and a proximal portion 111. Elongated body 110 is configured so that distal portion 111 may be navigated to a target site 1050 within patient 1000. For example, elongated body 110 may have an appropriate torque, stiffness, and / or flexibility as needed so that it may be navigated through delivery pathways to arrive at target site 1050. In some examples, one portion of elongated body (e.g., distal portion 113) may have different torque, stiffness, and flexibility compared to another portion (e.g., proximal portion 111) of elongated body.
[0026] In some examples, and as illustrated in FIG. 1 A, target site 1050 may include a portion of a heart 1001, such as a wall of a right atrium (RA) of heart 1001. A clinician may maneuver lead distal portion 112 through the vasculature of patient 1000 in order to position distal portion 112 at or near target site 1050. For example, the clinician may guide distal portion 112 through the superior vena cava (SVC) and into the RA. In some examples, other pathways or techniques may be used to guide lead distal portion 112 into other target implantation sites within the body of patient 1000.Atty Ref. No. A0013308W001
[0027] In the example of FIG. 1A, the target site 1050 is in a wall of the RA of heart 1001 and implantable medical device 100 is configured to provide neuromodulation to a vagus nerve (or ganglia thereof) of patient 1000. For example, once navigated to target site 1050, elongated body 110 may be configured to implant into cardiac tissue in the atrial wall to access ganglia plexi of the vagus nerve for neuromodulation thereof via an electrode on the distal portion 113 of elongate body 110. The vagus nerve may innervate the AVN, and neuromodulation of the vagus nerve may thereby control AV nodal conduction and / or a ventricular rate of heart 1001. For example, electrical neuromodulation therapy of the vagus nerve may significantly reduce the ventricular rate of heart 1001 during AF, e.g., due to conduction of the AF to the ventricles.
[0028] To this effect, implantable medical device 100 includes housing 190 that includes circuitry configured to provide electrical neuromodulation to a target tissue of patient 1000. For example, when implantable medical device 100 is positioned at a target site 1050, the circuitry may be configured to deliver a stimulating electrical signal via a first electrode (not shown in FIG. 1 A) on distal portion 112 of elongated body 110. This stimulating electrical signal is delivered to a target tissue (e.g., a nerve tissue of heart 1001). Example methods for electrical neuromodulation are described in commonly assigned, co-pending U.S. Patent Application No. 63 / 750,180, filed on January 27, 2025, entitled “Medical Device and Method for Delivering Atrial Arrhythmia Therapy”, that is incorporated herein by reference in its entirety. For example, electrical neuromodulation energy may be delivered via a pulse train of energy including multiple pulses having a certain pulse width and pulse amplitude. Each pulse in the pulse train is separated from the next pulse by an inter-pulse interval. The pulse energy may be increased by increasing the pulse amplitude and / or pulse width. In some examples, the pulse amplitude may be between 3.0 and 12.0 volts. In some examples, the pulse width may be 0.1 to 10 milliseconds (ms). In some examples, the inter-pulse interval may be 5 to 100 ms. The inter-pulse interval may be selected in combination with the pulse width to obtain a desired pulse frequency (e.g., the frequency of the pulses within the pulse train). In some examples, the pulse frequency may be 20 to 100 Hz, 30 to 80 Hz, 40 to 60 Hz. In other examples, a pulse train may be delivered as a continuous, e.g., oscillating, pulse waveform controlled by pulse parameters such as amplitude, frequency, period, and pulse train without having inter-pulse intervals.Atty Ref. No. A0013308W001
[0029] Additionally, housing 190 also includes circuitry configured to sense electrical signal from a tissue of patient 1000 that is not targeted for stimulation by the first electrode. For example, when implantable medical device 100 is positioned at a target site 1050, the circuitry is configured to sense an electrical signal via a second electrode (not shown in FIG. 1 A) on distal portion 112 of elongated body 110. The sensing signal is from cardiac tissue that is not the target of neuromodulation and may be indicative of a cardiac activity (e.g., P-wave, etc.) of heart 1001. In some examples, housing 190 also includes circuitry to send a pacing signal to the cardiac tissue. For example, the circuitry may send the pacing signal via the second electrode.
[0030] Accordingly, in the example of FIG. 1 A, implantable medical device 100 stimulates nerve tissue and senses cardiac tissue via the same elongated body 110, e.g., implantable medical lead. Thus, implantable medical device 100 may be configured such that the second electrode can sense an electrical signal of a cardiac tissue of the RA upon proper positioning of the first electrode proximate the nerve tissue. For example, the positioning of the first electrode to gain access to the ganglia plexi also appropriately positions the second electrode next to or proximate to the endocardial tissue of the RA. Accordingly, in some examples, a clinician may use implantable medical device 100 to both deliver neuromodulation therapy to the ganglia plexi and to sense and / or pace the activity of cardiac tissue without having to maneuver or implant another lead body to the target site 1050. This is helpful in determining unintentional stimulation of the cardiac tissue. It may also be helpful in decreasing implantation procedure time, etc. In some examples, the clinician may use implantable medical device 100 to deliver a pacing signal to the cardiac tissue.
[0031] While not shown in FIG. 1 A, in some examples, implantable medical device 100 may include additional elongated bodies (elongated leads) connected to housing 190. These additional leads may be used to sense and / or pace other locations of heart 1001 that is different from target site 1050. For example, implantable medical device 100 may include an elongated lead that is implanted in a location (e.g., ventricular chamber) of heart 1001 to pace and / or sense ventricular tissue of heart 1001. The elongated lead implanted in a ventricular chamber may help to determine when to deliver nerve electrical stimulation through the first electrode on elongated body 110. For example, in some types of neuromodulation therapies, the electrical stimulation to the nerve tissue may mostAtty Ref. No. A0013308W001effective when delivered during the ventricular refractory period of heart 1001. The additional elongated body implanted in a ventricular chamber may pace and sense the ventricular electrical signal. Implantable medical device 100 may determine, based on the ventricular electrical signal, that heart 1001 is in a ventricular refractory period.Accordingly, implantable medical device 100 delivers the electrical stimulation signal to the nerve tissue via the first electrode during the ventricular refractory period.
[0032] Implantable medical device 100 may not be limited to treatment of a human patient. Implantable medical device 100 may be implemented in non-human patients, such as primates, canines, equines, pigs, ovines, bovines, felines, etc. These non-human patients may undergo clinical or research therapies that may benefit from the subject matter of this disclosure.
[0033] FIG. IB is a conceptual diagram of a medical system 2000 including implantable medical device 100 of FIG. 1A and introducer sheath 2010, in accordance with techniques of this disclosure. In the example of FIG. IB, implantable medical device 100 is implanted at least partially within patient 1000 through incision site 10009.Although incision site 1009 is pictured in FIG. IB as being in the upper chest, in other examples, it may be located anywhere on the body of patient 1000.
[0034] In some examples, a clinician may insert elongated body 110 into and through a patient’s vasculature to target site 1050 within a body of patient 1000 (e.g., tissue of a heart of patient 1000) where a medical procedure may be undertaken. For example, system 2000 may include introducer sheath 2010 defining a lumen. The lumen of introducer sheath 2010 may be sized to allow insertion of elongated body 110 into introducer sheath 2010. Introducer sheath 2010 may first be inserted into and through patient’s vasculature to target site 1050, and thereafter implantable medical device 100 may be inserted through the lumen of introducer sheath 2010 to target site 1050. In some examples, the clinician may insert elongated body 110 under patient 1000’s sternum and to a target site within the body of patient 1000, rather than through the vasculature. Although incision site 1009 is pictured in FIG. IB as being in the upper chest, in other examples it may be located anywhere on the body of patient 102.
[0035] In some examples, medical device system 2000 may include a stylet and / or guidewire (not shown) for delivering distal portion 112 to target site 1050. For example, a guidewire may be first navigated through the vasculature and introducer sheath 2010 mayAtty Ref. No. A0013308W001be advanced over the guidewire. The guidewire is then withdrawn, leaving the introducer sheath 2010 in place. The elongated body 110 of implantable medical device is guided through the introducer sheath 2010. A stylet may help to maneuver the distal portion of implantable medical device 100 to the site 1050 and also may help to implant the medical device 100 into the heart (e.g., by piercing an electrode of the implantable medical device 100 into a heart tissue, etc.).
[0036] In some examples, the placement of elongated body 110 against target site 1050 and into implantation site 1051 may be done under imaging studies (e.g., fluoroscopy, etc.) to aid in the process in finding the appropriate implant location within the heart. Upon appropriate location determination, a distal tip of implantable medical device 100 may be pierced into implantation site in the RA. The introducer sheath 2010 may be removed from the patient and housing 190 may be connected to proximal portion of elongate body 110. In some examples, housing 190 may remain outside of the heart and / or body of patient 1000 (e.g., inserted under patient 1000 skin layers, etc.)
[0037] As discussed above and in relation to FIG. 1C, implantable medical device 100 is configured to stimulate target nerve tissue 130 for neuromodulation therapy and to also sense cardiac tissue using the same lead body. For example, elongated body 110 (i.e. a lead body) of implantable medical device 100 has a first electrode that is configured to stimulate target nerve tissue and a second electrode that is configured to sense cardiac tissue. Additionally, implantable medical device 100 comprises circuitry in housing 190 configured to cause the first electrode to deliver the stimulating signal to the nerve tissue and cause the second electrode to sense an electrical signal from the cardiac tissue of the heart. In some examples, implantable medical device is configured to deliver a second electrical signal (e.g. a pacing signal) via the second electrode to the cardiac tissue.
[0038] Accordingly, a clinician may use implantable medical device 100 to deliver the stimulating signal and to also sense cardiac signal without needing a separate lead body for sensing cardiac tissue. For example, with implantable medical device 100, upon appropriate positioning of the first electrode proximate to the target nerve tissue, the second electrode is also appropriately positioned to sense the cardiac tissue. In some examples, this may obviate the need for advancing another lead body into the heart for sensing cardiac tissue and thus not require time to determining appropriate target siteAtty Ref. No. A0013308W001and / or implantation site for the separate lead. This may reduce overall procedure time as it may reduce the time required for lead delivery and implantation.
[0039] FIG. 1C is a conceptual diagram of an example implantable medical device 100, in accordance with techniques of this disclosure. Implantable medical device 100 includes an elongated body 110 with a proximal portion 111, middle portion 112, and a distal portion 113. In some examples, one portion of elongated body (e.g., distal portion 113) may have different torque, stiffness, and flexibility characteristics as compared to another portion (e.g., proximal portion 111) of elongated body. Implantable medical device 100 also includes a housing 190 with circuitry 170.
[0040] Proximal portion 111 of elongated body 110 is connected to housing 190 via a connector section 114 located at the proximal end of proximal portion 111. Connector section 114 may include electrical connections that allow the electrically active portions of implantable medical device 100 (e.g., electrodes 120, 130, 140, etc.) to be electrically connected to circuitry 170 in housing. For example, an electrical conductor may extend from an electrode to connector section 114. That electrical conductor (or a subsequent electrical connection in contact with that electrical conductor), may be exposed on an outer surface of the connector section 114. Upon fitting the connector section 114 into an appropriately sixed port in housing 190, the electrical conductor electrically connects with an electrical region in the housing 190 that is configured to be controlled by circuitry 170. Accordingly, in some examples, connector section 114 may include a number of exposed electrical regions that correspond to the number of electrodes on implantable medical device 100. Additionally, connector section 114 may include mechanical features (e.g., threads, bearings, springs, etc.) that allow connector section 114 to securely mechanically mate with a corresponding port in housing 190. In some examples, the mating port and connector features may follow certain international standards (e.g., International Standard Organization (ISO) 5841-3, etc.) applicable in the medical industry. In some examples, an outer surface of proximal portion 111 outside of connector section 114 may be comprised of biocompatible non-conductive material such as a coating of parylene, polyurethane, silicone, epoxy or other biocompatible polymer.
[0041] Middle portion 112 of elongated body 110 extends from proximal portion 111 to distal portion 113. In some examples, an outer surface of middle portion 112 may beAtty Ref. No. A0013308W001comprised of biocompatible non-conductive material such as a coating of parylene, polyurethane, silicone, epoxy or other biocompatible polymer.
[0042] Distal portion 113 of elongated body 112 supports a second electrode 130. As shown in FIG. 1C, second electrode 130 may comprise a ring electrode and may be mounted on or assembled into distal portion 113. Second electrode 130 may be comprised of an electrically conductive material such as titanium, platinum, iridium, or alloys thereof. As shown in FIG. 1C, second electrode 130 may be a single continuous ring electrode. In other examples, second electrode may be comprised of a plurality of electrically active regions electrically connected to each other.
[0043] Second electrode 130 may be electrically connected to an electrical conductor (not shown) extending from proximal portion 111 to distal portion 113 of elongated body 110. This provides second electrode 130 electrical connection with circuitry 170 in housing 190.
[0044] Implantable medical device 100 also includes a first electrode 120 that extends from distal portion 113 of elongated body 110. As shown in FIG. 1C, first electrode 120 extends beyond a distal end of distal portion 113. In other words, FIG. 1C extends more distally than distal portion 113 of elongated body 110. In relation to second electrode 130, first electrode 120 extends more distally than first electrode 130.
[0045] As shown in FIG. 1C, first electrode 120 is in the shape of the helix.Accordingly, first electrode 120 may include a helical shaft composed of an electrically conductive material. The helical shaft may be connected (e.g., welded, etc.) to an electrical conductor (not shown) extending from proximal portion 111 to distal portion 113 of elongated body 110, thus providing first electrode 120 electrical connection with circuitry 170 in housing 190. A portion of the helical shaft may be insulated with a biocompatible non-conductive material, e.g. parylene or other materials listed herein, to avoid interference with second electrode 130 and to avoid stimulating non-target tissue with first electrode 120. A portion of the helical shaft is not insulated, leaving that portion electrically active. While shown as having a helical shape in FIG. 1C, in other examples, first electrode 120 may have other elongated configurations that allows for extension beyond distal portion 113 and implantation into a tissue. For example, first electrode 120 may be a dart electrode with a relatively straight insulated shaft member and a rounded electrically conductive tip.Atty Ref. No. A0013308W001
[0046] As shown in FIG. 1C, implantable medical device 110 also includes a third electrode 140 supported by distal portion 113. Third electrode 130 may comprise a ring electrode and may be mounted on or assembled into distal portion 113. Third electrode 130 may be comprised of an electrically conductive material such as titanium, platinum, iridium, or alloys thereof. As shown in FIG. 1C, third electrode 130 may be a single continuous ring electrode. Third electrode 130 may be electrically connected to an electrical conductor extending from proximal portion 111 to distal portion 113 of elongated body 110. This provides third electrode 130 electrical connection with circuitry 170 in housing 190. Third electrode 140 is at a location on distal portion 113 that is more proximal (i.e., closer to housing 190) than second electrode 130 and more proximal than first electrode 120.
[0047] In the implantable medical device 100 of FIG. 1C, first electrode 120 may act as a nerve stimulating cathode that is paired with third electrode 140 acting as an anode to deliver a bi-polar stimulating electrical signal to a target nerve tissue. For example, circuitry 170 is configured to deliver, using the first electrode 120, a neuromodulation therapy signal to a vagus nerve (e.g., ganglion plexi) located in the heart of a patient. The signal may be generated by circuitry 170 in housing 190 and propagated through the connected electrical conductor to first electrode 120.
[0048] Distal portion 113 may be advanced to a target site 1050, and upon location of an appropriate implantation site, implantable medical device 110 may be maneuvered such that first electrode 120 pierces into the tissue at the implantation site. As will be described in relation to FIG. 4, the implantable medical device 100 is positioned such that the electrically active portion of first electrode 120 may electrically stimulate the ganglion plexus of the vagus nerve. The insulated portion of first electrode 120 prevents the stimulation signal from affecting the cardiac tissue that surrounds the ganglion plexi. Accordingly, in some examples, the stimulation signal delivered by first electrode 120 stimulates the nerve tissue and does not stimulate the cardiac tissue.
[0049] In the implantable medical device 100 of FIG. 1C, second electrode 130 may act as sensing or pacing electrode to sense and / or pace cardiac tissue in close proximity to the target nerve tissue.
[0050] For example, when the first electrode 120 is appropriately positioned at the implantation site next to the ganglion plexi, the second electrode 130 may press against orAtty Ref. No. A0013308W001touch endocardial cardiac tissue in the RA. In other examples, second electrode 130 may be partially inserted into cardiac tissue in the RA such that a portion of second electrode 130 abuts the endocardium and another portion is inserted into the cardiac tissue (e.g., myocardium). Accordingly, electrical signals sensed by second electrode 130 may be indicative of right atrial cardiac activity (e.g., P-wave, etc.). Circuitry 170 is configured to cause second electrode 130 to capture the electrical signal. The signal may then be propagated through a connected conductor from second electrode 130. In some examples, second electrode 130 may act as a cathode paired with third electrode 140 as an anode to sense the cardiac tissue.
[0051] In some examples, second electrode 130 may act as a stimulating cathode that is paired with third electrode 140 acting as an anode to deliver bi-polar pacing electrical signals to the cardiac tissue. For example, circuitry 170 is configured to deliver, using second electrode 130 and third electrode 140, a pacing signal to the cardiac tissue. The signal may be generated by circuitry 170 in housing 190 and propagated through connected conductor to second electrode 120.
[0052] FIG. 2A is a conceptual diagram of an example implantable medical device 100, in accordance with techniques of this disclosure. Specifically, FIG. 2A shows a conceptual view of the multiple components of implantable medical device 100, including elongated body 110 and first electrode 120. Housing 170 is not shown in FIG. 2A. In FIG.2 A, the components associated with numeral 102 may be assembled over the components associated with numeral 101. Additionally, many components in FIG. 2 A are illustrated as transparent to better view underlying components. Features of FIG. 2 A may be substantially similar to like-named counterparts of FIGS. 1A-1C.
[0053] As shown in FIG. 2A, first electrode 120 is electrically connected to a first conductor 191. First conductor 191 may extend from proximal portion 111 (not shown in FIG. 2A) to distal portion 113 and electrically connects first electrode 120 to circuitry 170 in housing 190 via connector section 114. While first conductor 191 is shown in FIG. 2A as a non-coiled conductor (e.g., a cable conductor), in other examples, first conductor 191 may be comprised of a coiled conductor. First conductor 191 extends from first electrode 120 to connector section 114 of elongated body 110 and allows electrical connectivity of first electrode 120 to circuitry 170 in housing 190. First conductor 191 may be comprisedAtty Ref. No. A0013308W001of an electrically conductive metal such as nickel alloy MP35N, or other suitable materials as disclosed herein and as would be appreciated by those skilled in the art.
[0054] First electrode 120 comprises a helical shaft made from an electrically conductive material (e.g., titanium, etc.) and has an uncompressed length measured along a longitudinal axis of elongated body 110. The longitudinal axis is an axis extending between proximal portion 111 and distal portion 113 of elongated body 110, as shown by axis X in FIG. 2A. In some examples, first electrode 120 has a length of approximately 2-4 millimeters that extends distally from distal portion 113. This height may help to ensure that first electrode 120 is sufficiently proportioned such that first electrode 120 generates an area of stimulation that does not affect cardiac tissue not targeted for neuromodulation therapy.
[0055] Portion 122 of first electrode 121 is insulated by a non-conductive biocompatible material such as parylene or other suitable materials disclosed herein.Portion 121 of first electrode 122 is not insulated and is electrically active. In some examples, a total uncompressed length of first electrode 120 may be characterized as the sum of the pitch of the active portion 122 and the pitch of insulated portion 121. As the stimulating signal is delivered via electrically active portion 121 of first electrode 120, the relationship of insulated portion 122 to active portion 121 of first electrode 120 may affect the area of stimulation generated by first electrode 120. In some examples, electrically active portion 121 is from approximately a quarter turn to approximately half a turn of the helix. The non-conductive material on insulated portion 122 also helps to electrically insulate first electrode 120 from second electrode 130.
[0056] Additionally, a first insulating material 181 may be assembled over first conductor 191. First insulating material 181 may be comprised of a non-conductive material such as silicone, polytetrafluoroethylene, or materials disclosed herein. First insulating material 181 may extend from connector section 114 (not shown in FIG. 2 A) to distal portion 113 of elongated body 110 such that it electrically insulates first conductor 191. In this manner, first electrode 120 may be electrically insulated from second electrode 130. Additionally, in the connector section 114, first insulating material 181 may be configured such that it allows exposure of first conductor 191. For example, first insulating material 181 may end more distally in connector section 114 than first conductor 191 and first conductor 191 may be electrically connected to an electricalAtty Ref. No. A0013308W001contact disposed on the outer surface of connector section 114. This allows first conductor 191 to be exposed in connector section 114 so that it may be electrically connected to circuitry 170 in housing 190. In some examples, first insulating material 181 forms a separate co-centric layer in implantable medical device 100.
[0057] Second electrode 130 in FIG. 2 A may be a continuous ring electrode 130 made of a conductive material such as titanium, platinum, iridium or alloys thereof. Second electrode 130 may include a body defining a hole extending through the body. As will be described in relation to FIGS. 2B and 2C, when implantable medical device is assembled, first electrode 120 extends distally through this hole. In some examples, second electrode 130 includes an outer ring and an inner ring that is defined by the body. The outer ring of second electrode may be exposed on an outer surface of the implantable medical device 100 such that it directly contacts the treatment environment (e.g., heart of a patient, etc.). The inner ring is on the inside of elongated body 110 and does not directly contact the treatment environment.
[0058] Second electrode 130 is electrically connected to a second conductor 192. While second conductor 192 is shown as coiled conductor in FIG. 2A, in other examples, it may be a non-coiled conductor (e.g., a cable conductor). Second conductor 192 extends from second electrode 130 to connector section 114 of implantable medical device 100. Accordingly, second conductor 192 allows for electrical connectivity between second electrode 130 and circuitry 170 in housing 190. Additionally, second conductor 130 may be insulated by an insulating material applied to the coils of second conductor as opposed to being a co-centric layer of insulating material. This may allow second conductor 130 to be co-wound with another coiled conductor such that they are co-radial conductors.Second conductor 130 may extend from connector section 114 of elongated body 110 to second electrode 130. At connector section 114, second conductor 130 may be electrically connected to an electrical contact exposed on outer surface of connector section 114 such that second conductor 192 (and hence second electrode 130) may be electrically connected to circuitry 170 in housing 190.
[0059] A second insulating material 182 may be assembled over second conductor 192. This material may form a co-centric layer in implantable medical device 100 and may cover second conductor 192 and inner ring of second electrode 130. Second insulating material 182 does not cover outer ring of second electrode 130. Accordingly, electricalAtty Ref. No. A0013308W001signals may be sensed from or delivered to a cardiac tissue via second electrode 130. Second insulating material 182 may be comprised of a suitable bio-compatible insulating material, as disclosed herein, and thus may help to insulate distal portion 113 of implantable medical device 100 from a treatment environment. Additionally, second insulating material 182 may help in contributing to the flexibility, torque, and / or steerability of distal portion 113 of elongated body 110.
[0060] Elongated body 110 may also support a third electrode 140 at its distal portion 113. Third electrode 140 may comprise a single, continuous ring electrode that is assembled on an outer surface of distal portion 113 at a location that is more proximal to first electrode 120 and second electrode 130. Third electrode 140 may be comprised of a suitable conductive material, as disclosed herein and may be electrically connected (e.g., welded) to a third conductor 193. In some examples, and as shown in FIG. 2 A, third conductor is a coiled conductor. Third conductor 193 may be comprised of a suitable metal alloy (e.g., MP35N), or other materials as may be appreciated by one of ordinary skill in the art. The material of third conductor 193 may be insulted by a non-conductive material such that each individual coil is covered by the material. In this manner, the insulative material does not form an additional co-centric layer on top of third conductor 193. Accordingly, this may allow third conductor 193 to be co-wound with second conductor 192 such that second conductor 192 and third conductor 193 may be characterized as co-radial conductors. Third conductor 193 may extend from connector section 114 of elongated body 110 to third electrode 130. At connector section 114, third conductor 193 is electrically connected to an electrical contact exposed on an outer surface of connector section 114 such that third conductor 193 (and hence third electrode 140) is electrically connected to circuitry 170 in housing 190.
[0061] While second electrode 130 and third electrode 140 are shown and described as continuous ring electrodes in relation to FIG. 2 A, in other examples, second electrode 130 and / or third electrode 140 may be segmented ring electrodes. For example, portions of the ring of second electrode 130 may be coated with an electrically insulating coating, e.g., parylene, polyurethane, silicone, epoxy, or other insulating coating, to reduce the electrically conductive surface area of the ring electrode. For instance, one or more sectors of the ring may be coated to separate two or more electrically conductive exposed surface areas of second electrode 130. Reducing the electrically conductive surface area of secondAtty Ref. No. A0013308W001electrode 130, e.g., by covering portions of the electrically conductive ring with an insulating coating, may increase the electrical impedance of second electrode 130, and thereby reduce the electrical signal (current) delivered during a pacing pulse. A lower current drain conserves the power source, e.g., one or more rechargeable or non-rechargeable batteries, of implantable medical device 100.
[0062] Implantable medical device 100 may also include third insulating material 183 and fourth insulating material 184. These layers may help to insulate implantable medical device 100 from the environment and may be comprised of suitable bio-compatible insulative materials, as disclosed herein. Third insulating material 183 and / or fourth insulating material 184 may help in contributing to the flexibility, torque, and / or steerability of middle portion 112 and / or proximal portion 111 of elongated body 110. Additionally, these layers each form a separate co-centric layer on top of first conductor 131.
[0063] When implantable medical device 100 as shown in FIG. 2A is assembled, the components associated with numeral 102 are assembled over (on top of) components associated with 102. For example, at location A, first conductor 191 is an inner-most layer, with first insulating material 181 forming a co-centric layer over first conductor 191.Additionally, second conductor 192 and third conductor 193 may form a third co-centric layer on top of first insulating material 181 (due to their co-radial arrangement), third insulating material 183 may form a fourth co-centric layer, and fourth insulating material 184 may form a fifth co-centric layer over first conductor 191. At location B, first conductor 191 is an inner-most layer, with first insulating material 181 forming a co-centric layer over first conductor 191. Additionally, second conductor 192 may form a third co-centric layer over first insulating material 181. As such, when implantable medical device 100 is assembled, a portion of first electrode 120 extends through inner ring of second electrode 130. It is noted that while first conductor 191 is described as an inner-most layer, there may be other layers that is covered by first conductor 191 and not shown in FIG. 2A. For example, implantable medical device may include other inner co-centric layers.
[0064] FIG. 2B is a conceptual diagram of an example implantable medical device 100, in accordance with techniques of this disclosure. Specifically, FIG. 2B shows the implantable medical device 100 of FIG. 2A assembled. Housing 170 and connectorAtty Ref. No. A0013308W001section 114 are not shown in FIG. 2B. In FIG. 2B, some components are illustrated as being transparent to better show underlying components.
[0065] As seen in FIG. 2B, first electrode 120 extends distally through second electrode 130. First electrode 120 also extends beyond distal portion 113 of elongated body 110. Accordingly, in some examples, first electrode 120 defines a distal tip 160 or endpoint of implantable medical device 100. It should be noted that a portion of second conductor 192 that connects to second electrode 130 is not shown in FIG. 2B to provide a clearer view of the extension of first electrode 120 through second electrode 130.
[0066] FIG. 2C is a conceptual diagram of an example implantable medical device 100, in accordance with techniques of this disclosure. Specifically, FIG. 2C shows a closeup view of distal tip 160 and distal portion 113 of the implantable medical device 100 of FIG. 2B. As with FIG. 2B, a portion of second conductor 192 that connects to second electrode 130 is not shown in FIG. 2C to provide a clearer view of the extension of first electrode 120. Additionally, second electrode 130 is shown as being transparent to provide a clearer view of first electrode 120.
[0067] First electrode 120 extends from inside distal portion 113 of elongated body 110 to a point beyond distal portion 113 of elongated body 110. Thus, a 124 portion of first electrode 120 is inside elongated body 110 and a portion 123 of first electrode 120 is exposed to the treatment environment. Accordingly, first electrode 120 defines a distal tip 160 of implanted medical device 100. Portion 124 may be the portion of first electrode 120 that is pierced and implanted into the heart of a patient. In some examples, portion 123 has a length measured along X-axis of approximately 2-4 millimeters. In some examples, the length of portion 124 of first electrode helps to ensure that a stimulating electrical signal delivered through first electrode 120 stimulates target nerve tissue and does not stimulate non-target cardiac tissue.
[0068] As is shown in FIG. 2C, first electrode 120 is electrically connected to first conductor 191. In some examples, first electrode 120 is fixedly coupled in implantable medical device 100 such that its location in implantable medical device 100 is not longitudinally translatable along an X axis. In other words, the end of first electrode 190 that is connected to first connector 191 does not move more distally and does not move more proximally from proximal portion 111 of elongated body 110. As such, in some examples, the longitudinal position of first electrode 120 in relation to second electrodeAtty Ref. No. A0013308W001130 is fixed. First electrode 120 has a length as measured along the X-axis that is defined by the sum of portion 123 and portion 124.
[0069] First electrode 120 includes insulated portion 122 and active portion 121.Insulated portion 122 is illustrated in FIG. 2C as having a thicker line than the remainder of first electrode 120. Insulated portion 122 is electrically insulated such that the signal from first electrode 120 does not interfere with second electrode 130. Active portion 121 is electrically conductive and delivers a stimulating electrical signal to target nerve tissue.
[0070] In some examples, the amount of active portion 121 helps to ensure that a stimulating electrical signal delivered through first electrode 120 stimulates target nerve tissue and does not stimulate non-target cardiac tissue. In some examples, approximately a quarter turn to approximately a half-turn of first electrode 120 is active. A full turn of a helix may be characterized as a full circle of helix. One example of a full turn of first electrode 120 is symbolized by numeral 125 in FIG. 2C.
[0071] Second electrode 130 includes a body that defines an outer ring 131 and an inner ring 132. Outer ring 131 is assembled such that it on an outer surface of elongated body 110 and is contact with the treatment environment. In FIG. 2C, outer ring 131 is illustrated as being transparent to show the passage of first electrode 120. Inner ring 132 is located inside elongated body 110 at distal portion 113. A hole extends through the body of second electrode 130, allowing first electrode 120 to extend through the hole and exit distal portion 113 of elongated body.
[0072] FIG. 3 illustrates an example implantation site for implantable medical device 100, in accordance with the techniques disclosed herein. In some examples, the implantation site 1051 is in RA 1041 of heart 1001 of a patient. Implantation site 1051 may be on an atrial wall, proximate the orifice of the coronary sinus 1002 and the orifice of the inferior vena cava 1003. In some examples, and as shown in FIG. 3, implantation site 1051 may be closer to coronary sinus 1002 than inferior vena cava 1003. At implantation site 1051, nerve tissue (e.g., ganglionated plexi of vagus nerve) may be situated in an epicardial layer (e.g., connective tissue, fat tissue, etc.) located underneath the endocardium layer. Accordingly, first electrode 120 may be pierced through the endocardium layer at implantation site 1051 into the epicardial layer to access the nerve tissue situated there. Circuitry 170 may be configured to deliver, via first electrode 120, a stimulating electrical signal that is part of a neuromodulation therapy to the ganglionatedAtty Ref. No. A0013308W001plexi. Upon appropriate implantation of first electrode 120 into implantation site 1051, second electrode 130 is also appropriately situated such that it can sense cardiac activity of the endocardium layer in RA 1041. The signal sensed may be indicative of RA activity. In some examples, second electrode 130 abuts endocardium layer of the RA at implantation site 1051. It is appreciated that while FIG. 3 illustrates an example implantation site, devices and techniques disclosed herein may be implanted at other implantation sites within the heart. The implantation sites may include areas within the heart where nerve tissues may be surrounded by or in close proximity to cardiac tissue.
[0073] FIG. 4 shows an example implantation of implantable medical device 100, in accordance with techniques disclosed herein. As shown in FIG. 4, first electrode 120 is implanted into the tissues of the heart. First electrode 120 may be pierced through an endocardial layer 1021 of heart 1001 and into an epicardial layer 1030. Epicardial layer includes nerve tissue (e.g., ganglionated plexi 1012). Epicardial tissue may also include fat and connective tissue. First electrode 120 is situated in implantation location such that it located proximate ganglionated plexi 1012. In some examples, first electrode 120 may be situated such that an entirety of the portion that extends from distal portion 113 is inserted into the heart, and active portion 121 of first electrode 120 is located in the epicardial layer 130 proximate the ganglionated plexi 1012. In some examples, the length of the inserted portion of first electrode 120 is 2-4 millimeters. Additionally, in some examples, insulated portion 122 transverses myocardium layer 1020. In some examples, the distal tip of first electrode 120 is at most 1-2 millimeters spaced apart from the ganglionated plexi upon insertion of first electrode 120 into the heart. Due to limited active portion 121 of first electrode 120 and the length of first electrode 120 that extends from the distal portion, an area of stimulation 195 delivered via first electrode 120 is appropriately sized such that it stimulates nerve tissue but does not stimulate cardiac tissue (e.g., layers 1021 and / or layer 1020). Additionally, the longer structure (i.e., more distally extending as compared to the distal end of elongated body 100) of first electrode 120 advantageously reaches the ganglionated plexi, which allows for lower electrical stimulation parameters delivered via first electrode 120. The lower electrical stimulation parameters further reduces risk of stimulating cardiac tissue.
[0074] Upon implantation of first electrode 120 proximate ganglion plexi 1012, second electrode 130 is located next to endocardium layer 1021 of cardiac tissue.Atty Ref. No. A0013308W001Accordingly, second electrode 130 may sense activity of endocardium layer 1021. This endocardium layer 1021 is cardiac tissue in that its movement or activity is cardiac activity. In some examples, the signal sensed via second electrode 130 comprises signal indicative of a P-wave of the heart.
[0075] Additionally, in some examples, second electrode 130 may deliver a stimulating electrical signal to the endocardium layer. For example, this signal may be pacing signal to cause the cardiac tissue to contract. This may be done in instances where a sensing signal from second electrode 130 indicates atrial activity that is unexpected or irregular. The pacing signal to cardiac tissue is different from the electrical signal to nerve tissue in terms of pulse width, frequency, etc. and therefore does not stimulate the nerve tissue.
[0076] Implantable medical device 100 may also comprise a third electrode 140 supported on its distal portion. Third electrode 140 may act as an anode that is paired with first electrode 120 and paired with second electrode 130. In this example, first electrode 120 may be a cathode and second electrode 130 may be a cathode. In other examples, first electrode 120 may act as a unipolar electrode and / or second electrode 130 may act as unipolar electrode.
[0077] FIG. 5 shows an example method of using implantable medical device 100, in accordance with techniques disclosed herein. References to FIG. 1C, FIGS. 2B, and 2C may be used in relation to description of method of FIG. 5. At block 502, implantable medical device 100 is used to deliver a first stimulating electrical signal to a nerve tissue (e.g., vagus nerve) of a patient. As shown in FIG. 1C and FIGS. 2B-2C, implantable medical device 100 includes elongated body 110 with proximal portion 111 and distal portion 113. First electrode 120 extends distally from distal portion 113 and is used in the method 500 to deliver the stimulating electrical signal. Implantable medical device 100 also includes second electrode 120 that is supported by distal portion. At block 502, an electrical signal of cardiac tissue of the heart is sensed via second electrode 120. In some examples, the second electrical signal may be indicative of cardiac activity such as a P-wave.
[0078] Circuitry 170 in housing 190 may be used to control the electrical activity of first electrode 120 and second electrode 130. For example, circuitry 170 may be used toAtty Ref. No. A0013308W001cause first electrode 120 to deliver the stimulating electrical signal and to cause second electrode 130 to sense the electrical signal from the cardiac tissue.
[0079] In some examples, implantable medical device 100 includes a third electrode 140 supported at distal portion 113. Third electrode 140 is located on distal portion at a more proximal location than second electrode 130 and at a more proximal location on elongated body 110 than first electrode 120. In these examples, block 502 may include delivering the first stimulating electrical signal using first electrode 120 and third electrode 140. Additionally, in these examples, block 504 may include sensing the electrical signal of the cardiac tissue using second electrode 130 and third electrode 140. In these examples, first electrode 120 and second electrode 130 may be cathodes with third electrode 140 acting as an anode. In other examples, first electrode 120 and second electrodes 130 may be configured to generate unipolar signals. In some examples, circuitry 170 in housing 190 may be used to control the type of signal that is generated.
[0080] In some examples, method 500 may also include navigating implantable medical device 100 to a target site 1050 within the heart of a patient and implanting first electrode 120 into the implantation site 1051 in the heart. This block may be performed before block 502 in method 500. In some examples, the implantation site 1051 is in the right atrium. Accordingly, method 500 may include piercing an endocardium layer of the heart with first electrode 120 and advancing first electrode 120 through the endocardium layer into an epicardial layer of the heart. First electrode 120 is advanced such that active portion 121 of first electrode 120 is positioned proximate a nerve tissue (e.g., ganglionated plexi). As described above in relation to FIG. 4, upon appropriate placement of first electrode 120 proximate a target nerve tissue, second electrode 130 may also be appropriately positioned such that block 504 may be performed. Accordingly, in some examples, this does not require a step of re-positioning elongated body 110 of implantable medical device 100 to also perform block 504. Thus, in these examples, the positioning of the first electrode and the positioning of the second electrode may be characterized as occurring at the same time.
[0081] At block 506, a second stimulating electrical signal is delivered to the nerve tissue using first electrode 120. In some examples, the second stimulating signal may be based on the electrical signal determined at block 504. For example, the first stimulating electrical signal in block 502 may be part of a neuromodulation therapy for treating aAtty Ref. No. A0013308W001patient that is set by a clinician and programmed into circuitry 170. The first signal may be delivered via first electrode 120. Second electrode 130 may sense the second electrical signal of the cardiac tissue and propagate this signal to circuitry 170. Circuitry 170 may be configured to determine that the second electrical signal indicates irregular cardiac activity. Circuitry 170 may modify the neuromodulation therapy and send a second stimulating electrical signal to the first electrode 120 to be delivered to the nerve tissue as part of the modified neuromodulation therapy. In some examples, the second stimulating electrical signal is different from the first stimulating electrical signal. For example, the signals may be of different voltages, etc.
[0082] Method 500 may also include delivering a stimulating electrical signal to the cardiac tissue of the heart using second electrode 130. In some examples, this stimulating signal may be a pacing signal to control or modify the activity of cardiac tissue. In some examples, the stimulating electrical signal to the cardiac tissue is delivered using second electrode 130 and third electrode 140, with second electrode 130 acting as a cathode paired with third electrode 140 as the anode.
[0083] Although FIG. 5 shows a specific order of performance of blocks, method 500 is not limited to this order. For example, some of the functionalities shown in succession in method 500 may be performed in a different order, may be executed concurrently or with partial concurrence. For example, block 504 may be performed before block 502. In other words, the second electrode may be used to sense an electrical signal of a cardiac tissue of the heart. The electrical signal may indicate irregular cardiac activity. Block 502 may then be performed to deliver a stimulating electrical signal to a nerve tissue. In some examples, this may be performed in response to the electrical signal of the cardiac tissue of block 504. Additionally, while the different signals are referred to a “first” signal or a “second” signal, this does not limit the order in which the signals are delivered and / or captured.
[0084] FIG. 6 shows an example method of using implantable medical device 100, in accordance with techniques disclosed herein. References to FIG. 1C, FIGS. 2B, and 2C may be used in relation to description of method of FIG. 6.
[0085] At block 602, implantable medical device 100 senses an electrical signal indicative of ventricular activity of heart 1001. For instance, in some examples, implantable medical device 100 includes an additional elongated body (elongated lead)Atty Ref. No. A0013308W001connected to housing 190. The additional elongated body is separate from elongated body 110. The additional elongated body may have a distal end with at least one electrode positioned on the distal end. The distal end of the elongated body may be implanted within heart 1001 such that the at least one electrode is proximate to ventricular tissue of heart 1001 (e.g., implanted in ventricular chamber, etc.). This implantation site is different from implantation site 1051. Circuitry 170 in housing 190 may be used to control the electrical activity of the at least one electrode to deliver a stimulating electrical signal to the ventricular tissue and to sense an electrical signal indicative of ventricular activity. Based on the sensed ventricular activity and / or timing relative to delivery of a ventricular stimulating signal, circuitry 170 may determine that heart 1001 is in a ventricular refractory period.
[0086] At block 604, based on the determination made at block 606 that there a ventricular refractory period is occurring, first electrode 120 delivers the stimulating electrical tissue to the nerve tissue of heart 1001. In some examples, the stimulating electrical signal may be delivered via first electrode 120 and third electrode 140.
[0087] At block 606, second electrode 130 senses electrical signal from the cardiac tissue. This electrical signal may be indicative of whether there is atrial activity or there is a lack of atrial activity.
[0088] At block 608, based on a determination that there is a lack of atrial activity (determined at block 606), second electrode 130 delivers a pacing electrical signal to the atrial tissue. In some examples, the stimulating electrical signal may be delivered via second electrode 130 and third electrode 140.
[0089] FIG. 7 is a block diagram of circuitry 170 that may be enclosed within housing 190 to provide the functions of implantable medical device 100 according to one example. The electronic circuitry enclosed within housing 190 includes software, firmware and hardware that may cooperatively monitor cardiac signals, determine when a neuromodulation therapy is necessary, determine when pacing therapy is necessary, and deliver electrical signals (e.g., stimulating neuromodulation and / or pacing signals) to the patient's heart as needed according to programmed parameters. The housing includes control circuitry 551, communication circuitry 561, sensing circuitry 559, therapy delivery circuitry 555, a power source 565, and / or memory 563. Housing 190 may be configured toAtty Ref. No. A0013308W001fluidly isolate the circuitry of implantable medical device 100 from an environment in contact with an exterior surface of housing 190 (e.g., an internal environment of a patient).
[0090] Memory 563 may include any volatile, non-volatile, magnetic, or electrical non-transitory computer readable storage media, such as random-access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically-erasable programmable ROM (EEPROM), flash memory, or any other memory device.Furthermore, memory 563 may include non-transitory computer readable media storing instructions that, when executed by one or more processing circuits, cause control circuitry 551 and / or other circuits to nerve stimulation and cardiac sensing or other sensing and therapy delivery functions attributed to implantable medical device 100. The non-transitory computer-readable media storing the instructions may include any of the media listed above.
[0091] Control circuitry 551, therapy delivery circuitry 555, sensing circuitry 559, communication circuitry 561, and / or other circuitry may include fixed function circuitry and / or programmable processing circuitry. Control circuitry 551, therapy delivery circuitry 555, sensing circuitry 559, communication circuitry 561, and / or other circuitry may include any one or more of a microprocessor, a controller, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field-programmable gate array (FPGA), or equivalent discrete or analog logic circuitry. In some examples, control circuitry 551, therapy delivery circuitry 555, sensing circuitry 559, communication circuitry 561, and / or other circuitry may include multiple components, such as any combination of one or more microprocessors, one or more controllers, one or more DSPs, one or more ASICs, or one or more FPGAs, as well as other discrete or integrated logic circuitry. The functions attributed to control circuitry 551, therapy delivery circuitry 555, sensing circuitry 559, communication circuitry 561, and / or other circuitry herein may be embodied as software, firmware, hardware, or any combination thereof.
[0092] A power source 565 provides power to the circuitry of implantable medical device 100 including each of the components 551, 555, 561, 563, and 547 as needed. Power source 565 may include one or more energy storage devices, such as one or more rechargeable or non-rechargeable batteries. The connections between power source 565 and each of the other components 551, 555, 561, 563, and 547 are to be understood from the general block diagram of FIG. 7, but are not shown for the sake of clarity. ForAtty Ref. No. A0013308W001example, power source 565 is coupled to one or more charging circuits included in therapy delivery circuitry 555 for providing the power needed to charge holding capacitors included in therapy delivery circuitry 555 that are discharged at appropriate times under the control of control circuitry 551 for delivering stimulation signals (e.g., neuromodulation pulses, pacing pulses e.g.), according to an appropriate therapy mode. Power source 565 is also coupled to components of sensing circuitry 559 (e.g., sense amplifiers, analog-to-digital converters, switching circuitry, etc.), communication circuitry 561, and memory 563 to provide power to the various circuits as needed.
[0093] Control circuitry 551 communicates, e.g., via a data bus, with therapy delivery circuitry 555 and sensing circuitry 559 for sensing cardiac electrical signals and controlling delivery of neuromodulation therapies and delivery of cardiac pacing therapy. In some examples, the therapies may be in response to sensed cardiac events, e.g., P-waves, or the absence thereof. First electrode 120, second electrode 130, and third electrode 140 are electrically coupled to therapy delivery circuit 555 for delivering electrical stimulation signals to the patient's heart. Second electrode 130 and third electrode 140 are electrically coupled to sensing circuitry 559 for sensing cardiac electrical signals.
[0094] In some examples, sensing circuit 559 includes an atrial sensing channel.Second electrode 130 and third electrode 140 may be coupled to the atrial sensing channel for sensing atrial signals, e.g., P-waves indicative of the depolarization of the atrial myocardium. In some examples, sensing circuitry includes cardiac event detection circuitry for detecting P-waves, from the cardiac electrical signals received. The cardiac event detection circuitry of sensing circuitry 559 included may be configured to amplify, filter, digitize and rectify the cardiac electrical signal received from second electrode 130 to improve the signal quality for detecting cardiac electrical events. The cardiac event detection circuitry may include one or more sense amplifiers, filters, rectifiers, threshold detectors, comparators, analog-to-digital converters (ADCs), timers or other analog or digital components. A cardiac event sensing threshold, e.g., a P-wave sensing threshold, may be automatically adjusted by sensing channel under the control of control circuitry 551, e.g., based on timing intervals and sensing threshold values determined by control circuitry 551, stored in memory 563, and / or controlled by hardware, firmware and / or software of control circuitry 551 and / or sensing circuitry 559. While not shown in FIG. 7,Atty Ref. No. A0013308W001in some examples, sensing circuit 559 may also include a ventricular sensing channel. The ventricular sensing channel may be coupled to an additional elongated body separate from elongated lead body 110. The additional elongated body may be implanted in a ventricular chamber of heart 1001. The additional elongated body may include at least one electrode located at on its distal end that may be used for sensing and / or pacing ventricular tissue of heart 1001. The ventricular sensing channel may be coupled to the at least one electrode on the additional elongated body.
[0095] Therapy delivery circuitry 555 includes cardiac therapy circuitry 563 and nerve therapy circuitry 567. In some examples, cardiac therapy circuitry 563 includes atrial pacing circuitry. Each circuitry 563 and 567 includes charging circuitry, one or more charge storage devices such as one or more low voltage holding capacitors, an output capacitor, and switching circuitry that controls when the holding capacitor(s) are charged and discharged across the output capacitor to deliver a stimulation pulse to the electrode coupled to the respective circuitry 563 or 567. First electrode 120 and third electrode 140 may be coupled to nerve circuitry 567 as a bipolar cathode and anode pair for delivering stimulation electrical signals to nerve tissue as part of a neuromodulation therapy.
[0096] Cardiac therapy circuitry 563 may be coupled to second electrode 130 and third electrode 140 to deliver stimulation electrical signals to cardiac tissue. For example, these stimulation electrical signals may be atrial pacing pulses. While not shown in FIG. 7, in some examples, cardiac therapy circuitry 563 may be coupled to at least one electrode located on an additional elongated body that is separate from elongated boy 110. The additional elongated body may be implanted in a ventricular chamber of heart 1001.Cardiac therapy circuitry 563 may be coupled to the at least one electrode on this additional elongated body to deliver stimulation electrical signals to cardiac tissue. The stimulation electrical signals may be ventricular pacing pulses.
[0097] Charging of a holding capacitor of cardiac therapy circuitry 563 or nerve therapy circuitry 567 to a programmed therapy voltage amplitude and discharging of the capacitor for a programmed therapy pulse width may be performed by therapy delivery circuitry 555 according to control signals received from control circuitry 551. For example, a pace timing circuit included in control circuitry 551 may include programmable digital counters set by a microprocessor of the control circuitry 551 for controlling the basic pacing time intervals associated with various pacing modes. TheAtty Ref. No. A0013308W001microprocessor of control circuitry 551 may also set the amplitude, pulse width, polarity or other characteristics of the stimulation pulses delivered by the therapy delivery circuitry 555, which may be based on programmed values stored in memory 563.
[0098] Control parameters utilized by control circuitry 551 for sensing cardiac events, and controlling therapy delivery may be programmed into memory 563 via communication circuitry 561. Communication circuitry 561 includes a transceiver and antenna for communicating with an external device such as a programmer or home monitor, using radio frequency communication or other communication protocols. Under the control of control circuitry 5551, communication circuitry 561 may receive downlink telemetry from and send uplink telemetry to the external device.
[0099] In examples disclosed herein, implantable medical device 100 is configured to deliver a variety of therapies including neuromodulation therapy for atrioventricular node vagal stimulation (AVNS), and cardiac pacing therapies.
[0100] In some examples, control circuitry 551 may determine a cardiac event based on an electrical signal received by sensing circuitry 559 from second electrode 130 and cause nerve therapy circuitry 567 to send a stimulation electrical signal to first electrode 120. In some examples, control circuitry 551 may determine a cardiac event (e.g., a ventricular refractory period) based on an electrical signal received by sensing circuitry 559 from at least one electrode located on an additional elongated body separate from elongated body 110. Based on a determination that a ventricular refractory period is occurring, control circuitry may cause nerve therapy circuitry 567 to send a stimulation electrical signal to first electrode 120. Control circuitry 551 may determine a response of cardiac tissue from another electrical signal received by sensing circuitry 559 from second electrode 130 to determine whether the cardiac event has been resolved. In some examples, control circuitry 551 is configured to cause cardiac therapy circuitry 563 to deliver a stimulation electrical signal (e.g., pacing pulse) to cardiac tissue.
[0101] In some examples, control circuitry 551 is configured to cause nerve therapy circuitry 567 to deliver, via first electrode 120, a stimulation electrical signal to a nerve tissue as part of a neuromodulation therapy. Sensing circuitry 559 may receive from second electrode 130 an electrical signal indicative of cardiac tissue activity. Control circuitry 551 may determine from the signal that there is an irregular cardiac event (e.g., atrial fibrillation) occurring. Control circuitry 551 may modify a neuromodulation therapyAtty Ref. No. A0013308W001that is stored in memory 563 accordingly. In some examples, control circuitry 551 is configured to cause nerve therapy circuitry 567 to deliver a modified stimulation electrical signal via first electrode 120. Additionally, in some examples, control circuitry 551 is configured to cause cardiac therapy circuitry to deliver a stimulating signal to cardiac tissue via second electrode 130.
[0102] Therefore examples according to this disclosure in which a single lead body (e.g., elongated body 110) includes both nerve stimulation and cardiac sensing electrodes (e.g., electrodes 120 and 130) may: save time during an implantation procedure by removing the need for an additional lead; prevent excess harm to patient tissue by only stimulating necessary amount of tissue surrounding the implanted therapy electrode(s); and provide fewer instances of unintentional activation of patient cardiac tissue at the implantation site.
[0103] The following examples are illustrative of the techniques described herein.
[0104] Example 1. An implantable medical device comprising: an elongated body with a proximal portion and a distal portion; a first electrode extending distally from the distal portion, wherein the first electrode is configured to position proximate to a nerve tissue of a heart of a patient when the elongated body is implanted within the heart; a second electrode supported by the distal portion; and circuitry connected to first electrode and the second electrode via the proximal portion of the elongated body, the circuitry configured to: cause the first electrode to deliver a stimulating signal to the nerve tissue of the heart; and cause the second electrode to sense an electrical signal from a cardiac tissue of the heart.
[0105] Example 2. The medical device of example 1, comprising: a common electrode located proximally to the first electrode and proximally to the second electrode, wherein the circuitry is configured to: deliver the stimulating electrical signal via the first electrode and the common electrode, and sense the electrical signal via the second electrode and the common electrode.
[0106] Example 3. The medical device of any one or more of examples 1 or 2, wherein the nerve tissue comprises vagus nerve tissue.
[0107] Example 4. The medical device of example 3, wherein the vagus nerve tissue comprises ganglionated plexi.Atty Ref. No. A0013308W001
[0108] Example 5. The medical device of any one or more of examples 1 to 4, wherein the cardiac tissue comprises right atrial endocardial tissue.
[0109] Example 6. The medical device of any one or more of examples 1 to 5, wherein the first electrode comprises a helix.
[0110] Example 7. The medical device of any one or more of examples 1 to 6, wherein the second electrode comprises a ring electrode.
[0111] Example 8. The medical device of any one or more of examples 1 to 7, wherein the first electrode is configured to pierce into epicardial fat tissue of the heart.
[0112] Example 9. The medical device of any one or more of examples 1 to 8, wherein the first electrode is configured to deliver the stimulating signal to the nerve tissue and not the cardiac tissue when the elongated body is implanted within the heart.
[0113] Example 10. The medical device of any one or more of examples 1 to 9, wherein the second electrode comprises an electrode body with a hole extending through the body, wherein the first electrode extends through the hole beyond the distal portion of the elongated body, and wherein the first electrode defines a distal tip of the implantable medical device.
[0114] Example 11. The medical device of example 10, wherein the first electrode comprises an active portion configured to communicate the stimulating signal to the nerve tissue and an insulated portion proximal to the active portion, wherein the insulated portion extends through the hole of the sensing electrode, and wherein the active portion defines the distal tip of the implantable medical device.
[0115] Example 12. The medical device of any or more of examples 1 to 11, wherein first electrode comprises a tissue contacting portion defining a length of approximately 2-4 mm.
[0116] Example 13. The medical device of any one or more of examples 1 to 12, wherein the circuitry is configured to cause the second electrode to deliver a pacing electrical signal to the cardiac tissue.
[0117] Example 14. The medical device of any one or more of examples 1 to 13, wherein the medical device comprises an insulating material configured to electrically insulate the first electrode from the second electrode.
[0118] Example 15. A method comprising: delivering, via a first electrode of an implantable medical device, a first stimulating electrical signal to a nerve tissue of a heartAtty Ref. No. A0013308W001of a patient; and sensing, via a second electrode of the implantable medical device, an electrical signal of a cardiac tissue of the heart, wherein the implantable medical device comprises an elongated body with a proximal portion and a distal portion, wherein the first electrode extends distally from the distal portion, and wherein the second electrode is supported by the distal portion.
[0119] Example 16. The method of example 15, comprising: modifying a neuromodulation therapy based on the electrical signal; and delivering, via the first electrode, a second stimulating electrical signal consistent with modified neuromodulation therapy.
[0120] Example 17. The method of any one or more of examples 15 to 16, comprising: delivering, using the second electrode, a pacing electrical signal to the cardiac tissue.
[0121] Example 18. The method of any one or more of examples 15 to 18, comprising: navigating the implantable medical device to an implantation site within the heart; and positioning the first electrode proximate to the nerve tissue of the heart.
[0122] Example 19. The method of example 18, wherein the implantable medical device is navigated to the right atrium of the heart.
[0123] Example 20. The method of example 18, wherein the implantation site is located proximate to the coronary sinus opening in the right atrium.
[0124] Example 21. The method of example 20, comprising: positioning the second electrode proximate to the cardiac tissue of the heart at the same time the first electrode is positioned proximate to the nerve tissue of the heart.
[0125] Example 22. The method of any one or more of examples 15 to 21, wherein the nerve tissue comprises vagus nerve tissue.
[0126] Example 23. The method of example 22, wherein the vagus nerve tissue comprises ganglionated plexi.
[0127] Example 24. The method of any one or more of examples 15 to 23, wherein the first stimulating electrical signal is delivered via the first electrode and a common electrode located proximally to the first electrode and the second electrode on the implantable medical device; and wherein the second electrical signal is delivered via the second electrode and the common electrode.Atty Ref. No. A0013308W001
[0128] Example 25. The method of any one or more of examples 15 to 24, wherein the first stimulating signal is to stimulate the nerve tissue and not the cardiac tissue.
[0129] Example 26. The method of any one or more of examples 16 to 25, wherein the second electrode comprises an electrode body with a hole extending through the body, wherein the first electrode extends through the hole beyond the distal portion of the elongated body, and wherein the first electrode defines a distal tip of the implantable medical device.
[0130] Example 27. The method of example 26, comprising piercing right atrial endocardial tissue of the heart with the distal tip.
[0131] Example 28. The method of any one or more of examples 16 to 27, wherein the first electrode comprises an active portion and an insulated portion proximal to the active portion; and wherein first stimulating signal is delivered via the active portion.
Claims
Atty Ref. No. A0013308W001CLAIMSWHAT IS CLAIMED IS:
1. An implantable medical device comprising:an elongated body with a proximal portion and a distal portion;a first electrode extending distally from the distal portion, wherein the first electrode is configured to position proximate to a nerve tissue of a heart of a patient when the elongated body is implanted within the heart;a second electrode supported by the distal portion; andcircuitry connected to the first electrode and the second electrode via the proximal portion of the elongated body, the circuitry configured to:cause the first electrode to deliver a stimulating signal to the nerve tissue of the heart; andcause the second electrode to sense an electrical signal from a cardiac tissue of the heart.
2. The medical device of claim 1, comprising:a common electrode located proximally to the first electrode and proximally to the second electrode,wherein the circuitry is configured to:deliver the stimulating electrical signal via the first electrode and the common electrode, andsense the electrical signal via the second electrode and the common electrode.Atty Ref. No. A0013308W0013. The medical device of any one or more of claims 1 or 2, wherein the nerve tissue comprises vagus nerve tissue.
4. The medical device of claim 3, wherein the vagus nerve tissue comprises ganglionated plexi.
5. The medical device of any one or more of claims 1 to 4, wherein the cardiac tissue comprises right atrial endocardial tissue.
6. The medical device of any one or more of claims 1 to 5, wherein the first electrode comprises a helix.
7. The medical device of any one or more of claims 1 to 6, wherein the second electrode comprises a ring electrode.
8. The medical device of any one or more of claims 1 to 7, wherein the first electrode is configured to pierce into epicardial fat tissue of the heart.
9. The medical device of any one or more of claims 1 to 8, wherein the first electrode is configured to deliver the stimulating signal to the nerve tissue and not the cardiac tissue when the elongated body is implanted within the heart.
10. The medical device of any one or more of claims 1 to 9,wherein the second electrode comprises an electrode body with a hole extending through the body,Atty Ref. No. A0013308W001wherein the first electrode extends through the hole beyond the distal portion of the elongated body, andwherein the first electrode defines a distal tip of the implantable medical device.
11. The medical device of claim 10,wherein the first electrode comprises an active portion configured to communicate the stimulating signal to the nerve tissue and an insulated portion proximal to the active portion,wherein the insulated portion extends through the hole of the sensing electrode, andwherein the active portion defines the distal tip of the implantable medical device.
12. The medical device of any or more of claims 1 to 11, wherein the first electrode comprises a tissue contacting portion defining a length of approximately 2-4 mm.
13. The medical device of any one or more of claims 1 to 12, wherein the circuitry is configured to cause the second electrode to deliver a pacing electrical signal to the cardiac tissue.
14. The medical device of any one or more of claims 1 to 13, wherein the medical device comprises an insulating material configured to electrically insulate the first electrode from the second electrode.
